No pharmacokinetic or pharmacodynamic interaction between digoxin and ximelagatran, an oral direct thrombin inhibitor.

被引：0
|
作者：
Sarich, TC
Schützer, KM
Wollbratt, M
Wall, U
Kessler, E
Eriksson, UG
机构：
[1] AstraZeneca LP, Expt Med, Wilmington, DE USA
[2] AstraZeneca R&D Molndal, Expt Med, Molndal, Sweden
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4215
引用
收藏
页码：127B / 127B
页数：1
相关论文
共 50 条
  • [1] No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers
    Sarich, TC
    Schützer, KM
    Wollbratt, M
    Wall, U
    Kessler, E
    Eriksson, UG
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (08): : 935 - 941
  • [2] No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran
    Sarich, TC
    Schützer, KM
    Dorani, H
    Wall, U
    Kalies, I
    Ohlsson, L
    Eriksson, UG
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (08): : 928 - 934
  • [3] No clinically significant interaction between ximelagatran, an oral direct thrombin inhibitor and amiodarone
    Teng, R
    Sarich, TC
    Eriksson, UG
    Hamer, JE
    Gillette, S
    Carlson, GF
    Kowey, PR
    EUROPEAN HEART JOURNAL, 2003, 24 : 195 - 195
  • [4] Ximelagatran: An oral direct thrombin inhibitor
    Dager, WE
    Vondracek, TG
    McIntosh, BA
    Nutescu, EA
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (11) : 1881 - 1897
  • [5] No clinically significant interactions between the oral direct thrombin inhibitor ximelagatran and amiodarone, atorvastatin, or digoxin.
    Dorani, H
    Schützer, K
    Wollbratt, M
    Sarich, TC
    Eriksson, UG
    Teng, R
    Ohlsson, L
    Kessler, E
    Wall, U
    Kalies, I
    Hamer, JE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P78 - P78
  • [6] A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor
    Teng, RL
    Sarich, TC
    Eriksson, UG
    Hamer, JE
    Gillette, S
    Schützer, KM
    Carlson, GF
    Kowey, PR
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (09): : 1063 - 1071
  • [7] Ximelagatran: the first oral direct thrombin inhibitor
    Crowther, MA
    Weitz, JI
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (04) : 403 - 413
  • [8] Ximelagatran: An oral direct thrombin inhibitor for anticoagulant therapy
    Rossi, ML
    Zavalloni, D
    Belli, G
    Presbitero, P
    LETTERS IN DRUG DESIGN & DISCOVERY, 2005, 2 (07) : 503 - 506
  • [9] Melagatran and ximelagatran.: Anticoagulant, thrombin inhibitor.
    Sorbera, LA
    Bayès, M
    Castañer, J
    Silvestre, J
    DRUGS OF THE FUTURE, 2001, 26 (12) : 1155 - 1170
  • [10] Mild-to-moderate liver impairment has no influence on the pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor.
    Eriksson, UG
    Eriksson-Lepkowska, M
    Ohlsson, L
    Wåhlander, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P99 - P99
12345